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ABSTRACT – PURP OSE: To develop a simple and rapid HPLC method for measuring of four proton-pump 
inhibitors (PPIs), omeprazole (OPZ), pantoprazole (PPZ), lansoprazole (LPZ) and rabeprazole (RPZ) 
concentrations in human plasma. METHODS: Following a single step liquid–liquid extraction analytes along 
with an internal standard (IS) were separated using an isocratic mobile phase of phosphate buffer (10 
mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 with triethylamine) at flow rate of 1 mL/min on reverse phase 
TRACER EXCEL 120 ODS-A column at room temperature. RESULTS: Total analytical run time for selected 
PPIs was 10 min. The assays exhibited good linearity (r2>0.99) over the studied range of 20 to 2500 ng/mL for 
OPZ, 20 to 4000 ng/mL for PPZ, 20 to 3000 ng/mL for LPZ and 20 to 1500 ng/mL for RPZ. The recovery of 
method was equal or greater than 80% and lower limit of quantification (LLOQ) was 20 ng/mL for four PPIs. 
Coefficient of variation and error at all of the intra-day and inter-day assessment were less than 9.2% for all 
compounds. CONCLUSIONS: The results indicated that this method is a simple, rapid, precise and accurate 
assay for determination of four PPIs concentrations in human plasma. This validated method is sensitive and 
reproducible enough to be used in pharmacokinetic studies and also is time- and cost-benefit when selected PPIs 





Proton pump inhibitors (PPIs) are among the most 
extensively used drugs in the world. As a 
therapeutic group, the PPIs are highly useful for the 
relief of symptoms and healing of gastro esophageal 
reflux disease, peptic ulcer, Helicobacter pylori 
infection, prevention and treatment of nonsteroidal 
anti-inflammatory drugs (NSAIDs)-induced 
gastrointestinal lesions (complications) and 
management of hypersecretory states such as 
Zollinger-Ellison syndrome. Following oral 
administrations they are absorbed in the small 
intestine and reach via systemic circulation, to 
gastric parietal cells, where they bind to proton 
pump (H+/K + ATPase) and disturb the function of 
proton pump, thereby resulting in a potent acid 
inhibition (1). 
CYP2C19 is responsible for >80% of the 
metabolism of omeprazole (OPZ), pantoprazole 
(PPZ) and lansoprazole (LPZ), with CYP3A4 
undertaking most of the remaining metabolism. 






CYP2C19 as it undergoes nonenzymatic conversion 
to RPZ thioether. Polymorphism of CYP2C19 
influences pharmacokinetics and pharmaco-
dynamics of PPIs (2). 
A review of the literature revealed that several 
high performance liquid chromatographic (HPLC) 
methods have been used for determination of PPIs 
alone or with their metabolites in human plasma 
and urine (3-28). 
Hishinuma et al. reported a LC/MS/MS method 
for determination of LPZ and RPZ in human plasma 
(29). Although this method meets many or all 
generally accepted criteria for validated analysis of 
two PPIs, it involves costly equipment that is not 
available in many laboratories. 
The PPI pharmacophore is 2-
pyridylmethylsulfinylbenzimidazole (Figure 1). 
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PPZ, LPZ and RPZ) all contain this basic structural 
framework and differ only in the nature of 
substituents placed on the pyridine and 
benzimidazole rings (30). The practice of 
personalized medicine is now regarded as important 
in the prescription of medication. Therefore, it is 
necessary to understand the individual differences 
of the curative effect of PPIs in order to promote 
individualized medical care. Development of rapid 
and simple methods of quantification, applicable 
and validated for related drugs in a wide range of 
concentrations, also using available internal 
standard (IS) and simple operations in 
quantification of drug concentrations will be time- 
and cost-benefit. 
In this paper we describe a rapid and simple 
HPLC method for determination of OPZ, PPZ, LPZ 
and RPZ in human plasma using ultraviolet 
detection that allows rapid processing of large 
number of plasma samples. The method employed a 
mobile phase of pH 7.3, permitting the stability of 
PPIs and use of TRACER EXEL 120 ODS-A 
column, much less expensive than alkaline-resistant 
polymer-coated column. PPIs were also used as IS 
for other PPIs assay in our method. The assay 
method was validated according to FDA guidelines 
(31). 
 
MATERIALS AND METHODS 
 
Chemicals  
HPLC grade acetonitrile and methanol (Darmstadt, 
Germany) were used for the HPLC analysis. 
Deionized water was used from a Milli-Q system 
(Millipore, Bedford, MA, USA). Potassium 
dihydrogen phosphate, tert-butyl methyl ether and 
triethylamine were purchased from Merck 
(Darmstadt, Germany). OPZ, PPZ, LPZ and RPZ 
were obtained from Hetero Drugs Limited 
(Erragadda, Heydarabad, India) and their purity was 
over 99% by HPLC analysis.  All other chemicals 
were of analytical grade. 
 
Apparatus and chromatographic conditions 
The HPLC system (Waters chromatography 
division, Milford, MA, USA) consisted of a model 
600 pump, a 486 UV tunable absorbance detector, a 
7725i Rheodyne manual injector, a model 764 data 
module. Chromatographic separation of PPIs was 
achieved using a TRACER EXCEL 120 ODS-A (5 
µm 250 mm×4.6 mm i.d, Teknokroma) reverse 
phase analytical column with a µBondapak™ C18 
Guard column (5 μm, 120 Aº, Ireland). The mobile 
phase consisting of a mixture of phosphate buffer 
(10 mM)/acetonitrile (53/47, v/v adjusted pH to 7.3 
with triethylamine). The mobile phase was pumped 
at an isocratic flow rate of 1 mL/min at room 
temperature. The wavelength of UV detection was 
set at 302, 290, 285 and 284 nm for OPZ, PPZ, LPZ 
and RPZ assay, respectively. 
 
Preparation of standard solutions 
A stock solution (1 mg/mL) of OPZ, PPZ, LPZ and 
RPZ was prepared by dissolving 5mg of drugs in 
5mL of mobile phase. Working solutions were 
prepared from the stock solution by sequential 
dilution with mobile phase just before use. All 
solutions were protected from light by covering 
them with aluminum foil and stored in darkness at -
20ºC. In the case of OPZ and LPZ assays, PPZ was 
used as IS and in PPZ and RPZ assays, LPZ was 






























R4 R3 R2 R1 Compound 
OCH3 CH3 CH3 OCH3 Omeprazole 
OCHF2 H OCH3 OCH3 Pantoprazole 
H H CH3 OCH2CF3 Lansoprazole 
H H CH3 O(CH2)3CH3 Rabeprazole 
 
Figure 1. Chemical structures of selected PPIs 







Plasma samples (1 mL) were transferred to a 15-mL 
glass tube, and then 50 µL of IS working solution 
(10 µg/mL) was spiked. 4-mL aliquot of extraction 
solvent, tert-butyl methyl ether, was added. The 
sample was vortexed for 3 min. The sample was 
then centrifuged for 3 min at 3000 rpm. The organic 
layer (3 mL) was quantitatively transferred to a 6-
mL glass tube and evaporated at 37ºC under a 
stream of nitrogen. Then, the dried extract was 
reconstituted with 200 µL of mobile phase and a 50 




Recovery of each analyte was determined by 
comparing the peak area of the analyte extracted 
from the plasma with peak area obtained by the 
direct injection of pure standard analyte in mobile 
phase at three different concentrations containing 




To 950 µL of blank human plasma, 50 µL of 
working standard of OPZ, PPZ, LPZ or RPZ was 
added, yielding final concentrations of 20-2500 
ng/mL OPZ, 20-4000 ng/mL PPZ, 20-3000 ng/mL 
LPZ and 20-1500 ng/mL RPZ. To this mixture, 50 
µL of IS working solution was added to yield IS 
concentration of 500 ng/mL. Calibration samples 
were prepared for analysis as described above. Each 
calibration curve was analyzed three times with at 
least six different concentrations using the same 
HPLC conditions as described above. The peak area 
ratios of drugs to the IS for each of the standard 
solutions were calculated and plotted as a function 
of drug concentrations in human plasma. The 
calibration curves were acceptable only if they had 
correlation coefficients (r2) of 0.99 or greater. The 
acceptance criterion for each back-calculated 
standard concentration was 15% deviation from the 
nominal value except for the lower limit of 
quantification (LLOQ), which was set at 20% (31). 
 
Precision and accuracy 
To examine the accuracy and precision of our 
method, plasma spiked with four concentrations 
consisting of lower limit of quantification, low, 
middle and high concentrations of each analyte, 
were prepared. Intra-day precision and accuracy 
were evaluated by analyzing the spiked controls 
five times a day. This was repeated on three 
separate days to permit an assessment of inter-day 
accuracy and precision. Precision was evaluated at 
each concentration by comparing the values for the 
coefficient of variation: CV %=( SD/ mean 
measured concentration) × 100 and accuracy of the 
assay was determined in terms of % error by 
dividing the measured concentration minus the 
expected concentration to the expected 
concentration × 100. 
 
Stability 
Stability of plasma quality control (QC) samples of 
OPZ, PPZ, LPZ and RPZ were subjected to short-
term room temperature, was examined by keeping 
replicates of plasma quality control samples for 12 
h. Freeze–thaw stability of each analyte in human 
plasma samples were obtained over three freeze–
thaw cycles, by thawing at room temperature for 2–
3 h, refrozen for 12–24 h. Stability of drugs in 
human plasma was tested after storage at below -
80ºC for 3 months. The stability of standard 
solutions was also tested at room temperature for 2-
12 h and upon refrigeration (-20ºC) for 14 days. In 
all stability studies two quality control 
concentrations were used, 60 ng/mL as low quality 
control (LQC) for each analyte and 2200 ng/mL 
OPZ, 3500 ng/mL PPZ, 2500 ng/mL LPZ and 1200 
ng/mL RPZ as high quality control (HQC). For 
each concentration and each storage condition, six 
replicates were analyzed. The concentration of 
OPZ, PPZ, LPZ and RPZ after each storage period 
was related to the initial concentration as 
determined for the samples that were freshly 
prepared and processed immediately. Samples were 
considered stable if the assay values were within the 
acceptable limits of accuracy and precision (31). 
 
Application to pharmacokinetic study 
In order to test for utility of the described method in 
human pharmacokinetic studies, OPZ, PPZ, LPZ 
and RPZ were administered as a single oral dose in 
male subjects. A total of 30 subjects aged 20-45 
years, weighted 54-83 kg enrolled in the study. All 
the subjects were healthy and none were taking any 
medication. The ethics committee approved the 
protocol and volunteers have signed informed 
consent. The plasma samples were collected up to 
12 h after a single oral dose of 20 mg OPZ (Losec), 
20 mg PPZ (Pantozol), 30 mg LPZ (Zoton 






FasTab®) and 20 mg RPZ (Rabekind-Fast). Blood 
samples were collected in heparinized tubes and 
centrifuged for 15 min at 3000 rpm and the plasma 
was separated and stored at -80ºC until analysis. 
1mL plasma sample was spiked with 50 µL IS and 





Preliminary experiments were carried out to 
optimize the experimental parameters affecting 
chromatographic separation of OPZ, PPZ, LPZ and 
RPZ. To obtain chromatograms with good 
separation various columns, mixtures of mobile 
phase and different flow rates were investigated. 
For the assay of PPIs in human plasma a ODS-A 
C18 was found to be better than Nova-Pak C18 or 
inertsil ODS-3V C18. Various mixtures of phosphate 
buffer/acetonitrile were used as mobile phase and 
results indicated that phosphate buffer (10 
mM)/acetonitrile (53/47, adjusted pH to 7.3 with 
triethylamine) gives the best resolution. Also using 
different flow rates (in the range of 0.8-2 mL/min) 
revealed that the best separation was achieved on a 
flow rate of 1.00 mL/min of mobile phase. OPZ, 
RPZ, PPZ and LPZ were well separated with 
retention times of 5.7, 5.9, 6.4 and 8.1 min, 
respectively. Figure 2, 3, 4 and 5 show an overlay 
chromatograms for the blank human plasma (free of 
analyte and IS), human plasma spiked with IS, 
human plasma spiked with IS and OPZ, PPZ, LPZ 
or RPZ at their respective LLOQ (20 ng/mL 
concentration) and plasma sample obtained from a 
healthy subject after 3 h following oral 
administration of 20 mg OPZ, 20 mg PPZ, 30 mg 
LPZ and 20 mg RPZ. No interfering peaks from 
endogenous compounds are observed at the 
retention times of analytes. 
Linearity, precision and accuracy were 
determined to assess the performance of method. 
Linear calibration curves were constructed for each 
analyte. The correlation coefficients and equations 
for the calibration curves are shown in Table 1. 
Highly linear relationship between peak area ratios 
and human plasma concentration of drugs were 
evident over the broad concentration ranges studied 
(Table 1).  
 
The LLOQ as the lowest concentration on the 
calibration yielding acceptable precision (CV≤20%) 
and accuracy (80-120%) of theoretical value for four 
PPIs was 20 ng/mL (31). Table 2 shows the intra-day 
and inter-day assay validation quality report. 
Coefficient of variation and error at all of the intra-
day and inter-day assessment were less than 9.2%.  
 
 
Figure 2. Overlay chromatograms of (A) blank human 
plasma, (B) human plasma spiked with IS (500 ng/mL), 
(C) human plasma spiked with IS and OPZ at LLOQ, (D) 
plasma sample from a healthy subject following a 20mg 
oral dose of OPZ. 
 
 
Figure 3. Overlay chromatograms of (A) blank human 
plasma, (B) human plasma spiked with IS (500 ng/mL), 
(C) human plasma spiked with IS and PPZ at LLOQ, (D) 
plasma sample from a healthy subject following a 20mg 
oral dose of PPZ.  
Various organic solvents such as diethyl 
ether, methylene chloride, ethyl acetate, tert-butyl 
 






Table 1. Linear ranges and correlation coefficients of calibration curves. 
Analyte Retention time (min) Range of conc.(ng/mL) Equation * r 2 
OPZ 5.7 20-2500 Y=0.0071x - 0.0056 0.999 
     
RPZ 5.9 20-1500 Y=0.0014x + 0.0072 0.996 
     
PPZ 6.4 20-4000 Y=0.0017x - 0.001 0.999 
     
LPZ 8.1 20-3000 Y=0.0027x + 0.033  0.998 




methyl ether and dichloromethane alone or in 
combination were tested. The best solvent was 
found to be tert-butyl methyl ether, which allowed 
extraction of four PPIs in high yield. The recoveries 
of four PPIs were more than 80% (Table 3) and the 
dependence on concentration was negligible. 
 
 
Figure 4. Overlay chromatograms of (A) blank human plasma, 
(B) human plasma spiked with IS (500 ng/mL), (C) Human 
plasma spiked with IS and LPZ at LLOQ, (D) plasma sample 
from a healthy subject following a 30mg oral dose of LPZ. 
 
The stability experiments were aimed at 
testing all possible conditions that the samples 
might experience after collecting and prior the 
analysis. Acceptable analyte stability was 
demonstrated for all phases of storage and 
processing. All stability results are summarized in 
Table 4. Three freeze–thaw cycles and 12 h room 
temperature storage for low and high quality control 
samples indicated that OPZ, PPZ, LPZ and RPZ 
were stable in human plasma under these 
conditions. Quality control samples were stable for 
at least 3 months  if stored  frozen  at below −80ºC.  
 
 
Figure 5.  Overlay chromatograms of (A) blank human 
plasma, (B) human plasma spiked with IS (500 ng/mL), 
(C) Human plasma spiked with IS and RPZ at LLOQ, 
(D) plasma sample from a healthy subject following a 
20mg oral dose of RPZ.  
In addition, the stability of processed 
plasma sample was also tested.  It was found that 
four PPIs were stable at room temperature for 12 h 
and at -20ºC for 72 h. The standard solutions of 
OPZ, PPZ, LPZ and RPZ in mobile phase allowed 
standing at room temperature 12 h and at -20ºC for 
14 days. Mean serum concentration–time profiles 
OPZ, PPZ, LPZ and RPZ are shown in Figure 6 and 





Previous published methods focused only on 
analyzing one PPI. Our current method describes a 
basic assay method can be used to assay four PPIs 
when given separately. According to literature in 
many HPLC methods reported for determination of 







Table 2: Precision and accuracy of OPZ, PPZ, LPZ and RPZ determination in human plasma.















OPZ       
20 20.0 ± 1.6 8.09 0.15 19.1 ± 1.7 8.90 -4.50 
60 55.2 ± 3.5 6.34 -8.00 57.7 ± 2.9 5.03 -3.83 
1200 1091 ± 9 0.82 -9.08 1091 ± 29 2.66 -9.08 
2200 2335 ± 99 4.24 6.14 2270 ± 74 3.26 3.18 
       
PPZ       
20 20.9 ±  0.8 3.83 4.50 21.1 ± 1.3 6.16 5.50 
60 58.4 ± 4.2 7.19 -2.67 59.0 ± 3.1 5.29 -1.73 
2000 1910 ± 22 1.15 -4.50 1853 ± 63 3.40 -7.35 
3500 3602 ± 50 1.39 2.91 3289 ± 68 2.07 -6.03 
       
LPZ       
20 21.1 ± 1.4 6.63 5.50 20.3± 1.3 6.51 1.50 
60 62.1 ± 1.9 3.06 3.50 63.1 ± 2.9 4.51 5.17 
1500 1489 ± 41 2.75 -0.73 1524 ± 42 2.75 1.60 
2500 2351 ± 89 3.79 -5.96 2688 ± 52 1.91 7.52 
       
RPZ       
20 19.9 ± 1.8 9.05 -0.50 19.8 ± 1.8 9.09 -1.00 
60 61.4 ± 3.3 5.37 2.33 61.9 ± 3.6 5.82 3.17 
700 721 ± 15 2.08 3.00 724 ± 15 2.07 3.43 
1200 1229 ± 60 4.88 2.42 1219 ± 54 4.43 1.58 
OPZ, PPZ, LPZ and RPZ the chromatographic run 
time was between 8 and 25 min (3-9, 12-17) or ≥ 30 
min (10, 11) for OPZ, >10 min for RPZ (24, 26) 
and 11 min for LPZ (19, 21, 22). Uno et al. reported 
a simple and sensitive column-switching HPLC 
method for determination of LPZ and LPZ 
metabolites in plasma using liquid–liquid extraction 
but retention time was 19 min (28). In LC method 
for the determination of PPZ reported by 
Ramakrishna et al. retention time was 6.8 min but 
separation was done at 30ºC and relatively low 
recovery (48.7%) was observed (23). In our method 
retention times were less than 9 min for all 
compounds. The shorter run time allows for more 
samples to be analyzed per day. 
Due to poor stability of PPIs under acidic 
conditions, previous methods have performed 
chromatographic separation at pH of 7.0 or greater 
(3, 6, 8, 9, 26). Kobayashi et al. have reported a 
simple method for OPZ and its metabolites 
determination with a more expensive alkaline-
resistant column (6). Mihaly et al. reported a 
procedure using a mobile phase with pH of 7, but 
the method was not validated for its accuracy, while 
the  precision  was  carried out   using  a  single 
high    concentration   value   of   104.7  ng/mL (9).  
 
Table 3. Recoveries of OPZ, PPZ, LPZ and RPZ (n=6). 
Concentration (ng/mL) OPZ PPZ LPZ RPZ 
LQC* 84.5 ± 1.1 86.8 ± 1.0 83.3 ± 4.1 80.2 ± 1.1 
MQC** 82.3 ± 3.0 88.8 ± 2.0 80.9 ± 0.7 82.8 ± 1.0  
HQC*** 84.2 ± 1.0 85.4 ± 3.9 84.8 ± 1.1 81.6 ± 3.0  
*LQC is 60 ng/mL for each analyte, **MQC is 1200 ng/mL for OPZ, 2000 ng/mL for PPZ, 1500 ng/mL for LPZ 
and 700 ng/mL for RPZ, ***HQC is 2200 ng/mL for OPZ, 3500 ng/mL for PPZ, 2500 ng/mL for LPZ and 1200 
ng/mL for RPZ 
 








Table 5. Pharmacokinetic parameters of OPZ, PPZ, LPZ and RPZ after oral administration of 20 mg OPZ, 20 mg PPZ, 30 mg LPZ or 20 mg RPZ. 
Parameters OPZ 20 mg  
(n=8) 
PPZ 20 mg  
(n=8) 
LPZ 30 mg  
(n=8) 
RPZ 20 mg  
(n=6) 
Tmax (h) 2.00 ± 1.03 2.35 ± 0.28 1.65 ± 0.71 1.25 ± 0.35 
     
Cmax (ng/mL) 401 ± 179 889 ± 407 1132 ± 340 252 ± 35 
     






































stability for 12 h 
in plasma 
LQC* 60.4 2.15 0.67 61.7  3.40 2.83 59.8 2.01 -0.33 61.8 5.66 3.00 
HQC** 2253 1.11 2.41 3602 2.03 2.91 2660 2.29 6.40 1180 4.55 -1.67 
              
Three freeze and 
thaw cycles 
LQC* 59.6 2.35 -0.67 58.9  2.04 -1.83 59.6 3.52 -0.67 59.2 5.41 -1.33 
HQC** 2129 1.74 -3.23 3457 2.49 -1.23 2417 2.11 -3.32 1103 4.55 -8.08 
              
3 months stability 
at < -80ºC 
LQC* 54.1 4.62 -9.83 54.6 6.41 -9.00 55.7 3.77 -7.17 54.8 5.11 -8.67 
HQC** 2090 3.01 -5.00 3398 2.39 -2.91 2251 2.22 -9.96 1091 5.51 -9.08 
*LQC is 60 ng/mL for each analyte, **HQC is  2200 ng/mL for OPZ, 3500 ng/mL for PPZ, 2500 ng/mL for LPZ and 1200 ng/mL for RPZ 






Gonzalez et al. achieved a simultaneous 
determination of OPZ and its two metabolites by 
using a standard ODS C18 column with the mobile 
phase of pH 8.0 containing 0.015% nonylamine, 
and this prolonged the life of the column for 
analysis. However, the quantification limit (60 
ng/mL) of OPZ in that method is not sufficiently 






Figure 6. Mean plasma concentration vs time profile for 
each PPI following oral dosing to human subjects. 
 
However, we were able to overcome this limitation 
using mobile phase of pH 7.3 permitting stability of 
PPIs during analysis and use of TRACER EXCEL 
120 ODS-A column which is less expensive than 
polymer based column. 
Some previous methods used internal standards 
which are difficult to obtain commercially (7-9, 16, 
24). In this study a PPI was used as IS in the assay 
of other drugs in this class. Generally, large inter-
individual variations were observed in the 
pharmacokinetics of OPZ, PPZ and LPZ (2). 
Therefore, a more sensitive method having a wider 
range of capability is required for evaluating the 
precise pharmacokinetics of these drugs. The 
calibration curves obtained for each drug were 
linear over a wide range of concentrations (Table 
1). It seems more likely the ranges of 
concentrations were used for selected PPIs cover 
the majority of PPIs concentrations usually obtained 
in clinic.  
 
For studies that large numbers of samples are to 
be processed, solid phase extraction still remains as 
expensive alternative. The extraction procedure was 
used in this work yielded good recovery as well as 
high repeatability for all compounds (Table 3, 4). 
These two requisites are of great importance when 
an analytic method needs to be validated for 
providing reliable data. Both precision and accuracy 
at the LLOQ, low, medium and high concentrations 
of OPZ, PPZ, LPZ and RPZ in plasma were within 
acceptable limits for bioanalytical method (31). In 
the present study, we applied our method to 
determination of serum concentrations of OPZ, 
PPZ, LPZ and RPZ in a single oral dose. 
Pharmacokinetic parameters obtained in our 




In conclusion, we have developed and validated a 
rapid, simple and reproducible HPLC-UV method 
to determine  plasma levels of four PPIs, i.e. OPZ, 
PPZ, LPZ and RPZ in human plasma. Considering 
the fact that the present method involves a shorter 
running time, simple operations and use of PPIs as 
IS for assay of other drugs in this class, it may be 
used in similar studies as a time and cost effective 
alternative to other available methods. This method 
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HQC: high quality control, IS:  internal standard, 
LPZ: lansoprazole, LQC: low quality control, 
LLOQ: lower limit of quantification, MQC: 
middle quality control, OPZ: omeprazole, PPIs: 
proton pump inhibitors, PPZ: pantoprazole, QC: 
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